Gach J E, Berth-Jones J
Department of Dermatology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK.
J Dermatolog Treat. 2003 Dec;14(4):226-8. doi: 10.1080/09546630310015386.
We report the use of a combination of the tumour necrosis factor alpha (TNF alpha) inhibitor infliximab and hydroxyurea to achieve control of disabling psoriasis and psoriatic arthritis. Our patient had psoriasis that proved resistant to conventional therapy including vitamin D analogues, topical steroids, dithranol, crude coal tar, narrow band UVB, bath PUVA and acitretin. She subsequently responded to hydroxyurea 1 g daily combined with infliximab infusions repeated at three monthly intervals which led to satisfactory control of her psoriasis and psoriatic arthritis. She has not reported any side-effects from this treatment regimen and her full blood count has remained normal.
我们报告了使用肿瘤坏死因子α(TNFα)抑制剂英夫利昔单抗和羟基脲联合治疗来控制致残性银屑病和银屑病关节炎的情况。我们的患者患有银屑病,事实证明其对包括维生素D类似物、外用类固醇、蒽林、粗煤焦油、窄谱UVB、浴用补骨脂素紫外线A光化学疗法(bath PUVA)和阿维A在内的传统治疗均有耐药性。她随后对每日1克羟基脲联合每三个月重复一次的英夫利昔单抗输注产生了反应,这使得她的银屑病和银屑病关节炎得到了满意的控制。她没有报告该治疗方案产生的任何副作用,且她的全血细胞计数一直保持正常。